Avalon GloboCare Corp. (NASDAQ:CHGA) Shares Shorted: Short Interest Down 51.8% in September

Posted by Chris Copeland on Oct 1st, 2026

Avalon GloboCare Corp. (NASDAQ:CHGA – Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 33,188 shares, a decrease of 51.8% from the August 31st total of 68,808 shares. Approximately 3.9% of the shares of the stock are short sold. Based on an average trading volume of 48,548 shares, the short-interest ratio is presently 0.7 days.

Analyst Ratings Changes

Separately, Weiss Ratings raised Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, August 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Avalon GloboCare has a consensus rating of “Sell”.

Check Out Our Latest Stock Report on Avalon GloboCare

Avalon GloboCare Stock Down 6.2%

CHGA stock opened at $2.25 on Thursday. Avalon GloboCare has a 52 week low of $1.79 and a 52 week high of $49.20. The company has a fifty day simple moving average of $3.84 and a two-hundred day simple moving average of $6.48. The firm has a market capitalization of $2.52 million, a P/E ratio of -0.16 and a beta of -0.05.

Avalon GloboCare (NASDAQ:CHGA – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($2.80) earnings per share (EPS) for the quarter.

Avalon GloboCare Company Profile

(Get Free Report)

Avalon GloboCare Corp. is a life sciences company focused on developing cell-based technologies and precision medicine applications. Its work has included regenerative medicine, cancer diagnostics, and therapeutic platforms designed to support the development of personalized healthcare treatments.

The company has also pursued technologies involving cellular processing, biomanufacturing, and related laboratory services. Avalon GloboCare’s activities have included collaborations and development programs intended to translate emerging cell and molecular science into clinical and commercial applications.

Avalon GloboCare was established in the mid-2010s and has been headquartered in Freehold, New Jersey.